Possible renoprotection by vitamin D in chronic renal disease: Beyond mineral metabolism

Nature Reviews Nephrology

Volumn 5, Issue 12, 2009, Pages 691-700

  Doorenbos, Carolina R C ^a   Van Den Born, Jacob ^a   Navis, Gerjan ^a   De Borst, Martin H ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ALISKIREN; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; ANTIFIBROTIC AGENT; CALCITRIOL; COLECALCIFEROL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LOSARTAN; RENIN INHIBITOR; VITAMIN D; VITAMIN D BINDING PROTEIN; VITAMIN D DERIVATIVE;

ANTIINFLAMMATORY ACTIVITY; CHRONIC KIDNEY DISEASE; CLINICAL TRIAL; CYTOKINE PRODUCTION; DIABETIC NEPHROPATHY; DIALYSIS; DRUG EFFECT; DRUG EFFICACY; DRUG HYDROXYLATION; HELPER CELL; HUMAN; HYPERTENSION; IMMUNOMODULATION; JUXTAGLOMERULAR CELL; KIDNEY FAILURE; KIDNEY FUNCTION; KNOCKOUT MOUSE; MINERAL METABOLISM; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PATHOPHYSIOLOGY; PHARMACOLOGICAL BLOCKING; PRIORITY JOURNAL; PROTEINURIA; RENAL PROTECTION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; ULTRAVIOLET B RADIATION; UREMIA; VITAMIN D DEFICIENCY; VITAMIN D METABOLISM; VITAMIN SUPPLEMENTATION;

HUMANS; KIDNEY; KIDNEY DISEASES; MINERALS; RENIN-ANGIOTENSIN SYSTEM; VITAMIN D; VITAMIN D DEFICIENCY;

EID: 73849129217     PISSN: 17595061     EISSN: 1759507X     Source Type: Journal    
DOI: 10.1038/nrneph.2009.185     Document Type: Review

References (117)

1. Holick, M. F. Vitamin D deficiency. N. Engl. J. Med. 357, 266-281 (2007).
2. Nykjaer, A. et al. An endocytic pathway essential for renal uptake and activation of the steroid 25-(OH) vitamin D3. Cell 96, 507-515 (1999).
3. Zhong, Y., Armbrecht, H. J. & Christakos, S. Calcitonin, a regulator of the 25-hydroxyvitamin D3 1alpha-hydroxylase gene. J. Biol. Chem. 284, 11059-11069 (2009).
4. Turunen, M. M., Dunlop, T. W., Carlberg, C. & Vaisanen, S. Selective use of multiple vitamin D response elements underlies the 1 alpha, 25-dihydroxyvitamin D3-mediated negative regulation of the human CYP27B1 gene. Nucleic Acids Res. 35, 2734-2747 (2007).
5. Liu, S. et al. Fibroblast growth factor 23 is a counter-regulatory phosphaturic hormone for vitamin D. J. Am. Soc. Nephrol. 17, 1305-1315 (2006).
6. Urakawa, I. et al. Klotho converts canonical FGF receptor into a specific receptor for FGF23. Nature 444, 770-774 (2006).
7. Shimada, T. et al. Targeted ablation of Fgf23 demonstrates an essential physiological role of FGF23 in phosphate and vitamin D metabolism. J. Clin. Invest. 113, 561-568 (2004).
8. Carlberg, C. & Seuter, S. A genomic perspective on vitamin D signaling. Anticancer Res. 29, 3485-3493 (2009).
9. Christakos, S., Raval-Pandya, M., Wernyj, R. P. & Yang, W. Genomic mechanisms involved in the pleiotropic actions of 1,25-dihydroxyvitamin D3. Biochem. J. 316 (Pt 2), 361-371 (1996).
10. Ginde, A. A., Liu, M. C. & Camargo, C. A. Jr. Demographic differences and trends of vitamin D insufficiency in the US population, 1988-2004. Arch. Intern. Med. 169, 626-632 (2009).
11. White, J. H. Profiling 1,25-dihydroxyvitamin D3- regulated gene expression by microarray analysis. J. Steroid Biochem. Mol. Biol. 89-90, 239-244 (2004).
12. Bosse, Y., Maghni, K. & Hudson, T. J. 1alpha, 25-dihydroxy-vitamin D3 stimulation of bronchial smooth muscle cells induces autocrine, contractility, and remodeling processes. Physiol. Genomics 29, 161-168 (2007).
13. ellis, B. C., Gattoni-Celli, S., Mancia, A. & Kindy, M. S. The vitamin D3 transcriptomic response in skin cells derived from the Atlantic bottlenose dolphin. Dev. Comp. Immunol. 33, 901-912 (2009).
14. Towsend, K. et al. Identification of VDRresponsive gene signatures in breast cancer cells. Oncology 71, 111-123 (2006).
15. Wu-Wong, J. R., Nakane, M., Ma, J., Ruan, X. & Kroeger, P. e. VDR-mediated gene expression patterns in resting human coronary artery smooth muscle cells. J. Cell Biochem. 100, 1395-1405 (2007). (Pubitemid 46515574)
16. Tan, X., Wen, X. & Liu, Y. Paricalcitol inhibits renal inflammation by promoting vitamin D receptor-mediated sequestration of NF-kappaB signaling. J. Am. Soc. Nephrol. 19, 1741-1752 (2008).
17. Norman, A. W. Minireview: vitamin D receptor: new assignments for an already busy receptor. Endocrinology 147, 5542-5548 (2006).
18. Dusso, A. S., Brown, A. J. & Slatopolsky, e. Vitamin D. Am. J. Physiol. Renal Physiol. 289, F8-F28 (2005).
19. Holick, M. F. & Garabedian, M. in Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism (ed. Favus, M. J.) 129-137 (Lippincott Williams & Wilkins, Washington, DC, 2006).
20. Holick, M. F. Resurrection of vitamin D deficiency and rickets. J. Clin. Invest. 116, 2062-2072 (2006).
21. Kumar, R., Schaefer, J., Grande, J. P. & Roche, P. C. Immunolocalization of calcitriol receptor, 24-hydroxylase cytochrome P-450, and calbindin D28k in human kidney. Am. J. Physiol. 266, F477-F485 (1994).
22. Zhang, Z. et al. 1,25-Dihydroxyvitamin D3 targeting of NF-kappaB suppresses high glucose-induced MCP-1 expression in mesangial cells. Kidney Int. 72, 193-201 (2007).
23. Zhang, Z. et al. Renoprotective role of the vitamin D receptor in diabetic nephropathy. Kidney Int. 73, 163-171 (2008).
24. Vieth, R. The role of vitamin D in the prevention of osteoporosis. Ann. Med. 37, 278-285 (2005).
25. Bischoff-Ferrari, H. A., Giovannucci, e., Willett, W. C., Dietrich, T. & Dawson-Hughes, B. estimation of optimal serum concentrations of 25-hydroxyvitamin D for multiple health outcomes. Am. J. Clin. Nutr. 84, 18-28 (2006).
26. Lips, P. Which circulating level of 25-hydroxyvitamin D is appropriate? J. Steroid Biochem. Mol. Biol. 89-90, 611-614 (2004).
27. Malabanan, A., Veronikis, I. e. & Holick, M. F. Redefining vitamin D insufficiency. Lancet 351, 805-806 (1998).
28. Jones, G. Pharmacokinetics of vitamin D toxicity. Am. J. Clin. Nutr. 88, 582S-586S (2008).
29. Matsuoka, L. Y., Ide, L., Wortsman, J., MacLaughlin, J. A. & Holick, M. F. Sunscreens suppress cutaneous vitamin D3 synthesis. J. Clin. Endocrinol. Metab. 64, 1165-1168 (1987).
30. Scragg, R. & Camargo, C. A. Jr. Frequency of leisure-time physical activity and serum 25-hydroxyvitamin D levels in the US population: results from the Third National Health and Nutrition examination Survey. Am. J. Epidemiol. 168, 577-586 (2008).
31. Wortsman, J., Matsuoka, L. Y., Chen, T. C., Lu, Z. & Holick, M. F. Decreased bioavailability of vitamin D in obesity. Am. J. Clin. Nutr. 72, 690-693 (2000).
32. Binkley, N. et al. Assay variation confounds the diagnosis of hypovitaminosis D: a call for standardization. J. Clin. Endocrinol. Metab. 89, 3152-3157 (2004).
33. Singh, R. J. Are clinical laboratories prepared for accurate testing of 25-hydroxy vitamin D? Clin. Chem. 54, 221-223 (2008).
34. Yates, A. M. et al. Interlaboratory variation in 25-hydroxyvitamin D2 and 25-hydroxyvitamin D3 is significantly improved if common calibration material is used. Clin. Chem. 54, 2082-2084 (2008).
35. Looker, A. C. et al. Serum 25-hydroxyvitamin D status of the US population: 1988-1994 compared with 2000-2004. Am. J. Clin. Nutr. 88, 1519-1527 (2008).
36. Carter, G. D. 25-Hydroxyvitamin D assays: the quest for accuracy. Clin. Chem. 55, 1300-1302 (2009).
37. Gonzalez, e. A., Sachdeva, A., Oliver, D. A. & Martin, K. J. Vitamin D insufficiency and deficiency in chronic kidney disease. A single center observational study. Am. J. Nephrol. 24, 503-510 (2004).
38. Jean, G., Charra, B. & Chazot, C. Vitamin D deficiency and associated factors in hemodialysis patients. J. Ren. Nutr. 18, 395-399 (2008).
39. LaClair, R. e. et al. Prevalence of calcidiol deficiency in CKD: a cross-sectional study across latitudes in the United States. Am. J. Kidney Dis. 45, 1026-1033 (2005).
40. Levin, A. et al. Prevalence of abnormal serum vitamin D, PTH, calcium, and phosphorus in patients with chronic kidney disease: results of the study to evaluate early kidney disease. Kidney Int. 71, 31-38 (2007).
41. Barreto, D. V. et al. Vitamin D affects survival independently of vascular calcification in chronic kidney disease. Clin. J. Am. Soc. Nephrol. 4, 1128-1135 (2009).
42. Cuppari, L., Carvalho, A. B. & Draibe, S. A. Vitamin D status of chronic kidney disease patients living in a sunny country. J. Ren. Nutr. 18, 408-414 (2008).
43. Wolf, M. et al. Vitamin D levels and early mortality among incident hemodialysis patients. Kidney Int. 72, 1004-1013 (2007).
44. Wang, A. Y. et al. Serum 25-hydroxyvitamin D status and cardiovascular outcomes in chronic peritoneal dialysis patients: a 3-y prospective cohort study. Am. J. Clin. Nutr. 87, 1631-1638 (2008).
45. Zittermann, A., Gummert, J. F. & Borgermann, J. Vitamin D deficiency and mortality. Curr. Opin. Clin. Nutr. Metab. Care doi:10.1097/ MCO.0b013e3283310767
46. Autier, P. & Gandini, S. Vitamin D supplementation and total mortality: a meta-analysis of randomized controlled trials. Arch. Intern. Med. 167, 1730-1737 (2007).
47. Melamed, M. L., Michos, e. D., Post, W. & Astor, B. 25-hydroxyvitamin D levels and the risk of mortality in the general population. Arch. Intern. Med. 168, 1629-1637 (2008).
48. Wang, T. J. et al. Vitamin D deficiency and risk of cardiovascular disease. Circulation 117, 503-511 (2008).
49. Dobnig, H. et al. Independent association of low serum 25-hydroxyvitamin D and 1,25-dihydroxyvitamin D levels with all-cause and cardiovascular mortality. Arch. Intern. Med. 168, 1340-1349 (2008).
50. Hsia, J. et al. Calcium/vitamin D supplementation and cardiovascular events. Circulation 115, 846-854 (2007).
51. Wallis, D. e. & Penckofer, S. Letter by Wallis and Penckofer regarding article, "Calcium/vitamin D supplementation and cardiovascular events". Circulation 116, e86 (2007).
52. Pettifor, J. M. in Vitamin D (eds Feldman, D., Pike, J. W. & Glorieux, F. H.) 1065-1084 (elsevier Academic Press, Boston, 2005).
53. Avenell, A., Gillespie, W. J., Gillespie, L. D. & O'Connell, D. Vitamin D and vitamin D analogues for preventing fractures associated with involutional and post-menopausal osteoporosis. Cochrane Database of Systematic Reviews Issue 2. Art. No.: CD000227 doi:10.1002/ 14651858.CD000227.pub3 (2009).
54. Tang, B. M., eslick, G. D., Nowson, C., Smith, C. & Bensoussan, A. Use of calcium or calcium in combination with vitamin D supplementation to prevent fractures and bone loss in people aged 50 years and older: a meta-analysis. Lancet 370, 657-666 (2007).
55. Chapuy, M. C. et al. Vitamin D3 and calcium to prevent hip fractures in the elderly women. N. Engl. J. Med. 327, 1637-1642 (1992).
56. Dawson-Hughes, B., Harris, S. S., Krall, e. A. & Dallal, G. e. effect of calcium and vitamin D supplementation on bone density in men and women 65 years of age or older. N. Engl. J. Med. 337, 670-676 (1997).
57. Grant, A. M. et al. Oral vitamin D3 and calcium for secondary prevention of low-trauma fractures in elderly people (Randomised evaluation of Calcium Or vitamin D, ReCORD): a randomised placebo-controlled trial. Lancet 365, 1621-1628 (2005).
58. de Boer, I. H., Ioannou, G. N., Kestenbaum, B., Brunzell, J. D. & Weiss, N. S. 25-Hydroxyvitamin D levels and albuminuria in the Third National Health and Nutrition examination Survey (NHANeS III). Am. J. Kidney Dis. 50, 69-77 (2007).
59. Lambers Heerspink, H. J. et al. The Selective Vitamin D Receptor Activator for Albuminuria Lowering (VITAL) Study: study design and baseline characteristics. Am. J. Nephrol. 30, 280-286 (2009).
60. Inaguma, D. et al. Relationship between serum 1,25-dihydroxyvitamin D and mortality in patients with pre-dialysis chronic kidney disease. Clin. Exp. Nephrol. 12, 126-131 (2008).
61. Ravani, P. et al. Vitamin D levels and patient outcome in chronic kidney disease. Kidney Int. 75, 88-95 (2009).
62. de Boer, I. et al. 25-Hydroxyvitamin D levels inversely associate with risk for developing coronary artery calcification. J. Am. Soc. Nephrol. 20, 1805-1812 (2009).
63. Chonchol, M. & Scragg, R. 25-Hydroxyvitamin D, insulin resistance, and kidney function in the Third National Health and Nutrition examination Survey. Kidney Int. 71, 134-139 (2007). (Pubitemid 46094686)
64. Martins, D. et al. Prevalence of cardiovascular risk factors and the serum levels of 25-hydroxyvitamin D in the United States: data from the Third National Health and Nutrition examination Survey. Arch. Intern. Med. 167, 1159-1165 (2007).
65. Marcen, R. et al. Prevalence of osteoporosis, osteopenia, and vertebral fractures in long-term renal transplant recipients. Transplant. Proc. 39, 2256-2258 (2007).
66. Pichette, V. et al. Long-term bone loss in kidney transplant recipients: a cross-sectional and longitudinal study. Am. J. Kidney Dis. 28, 105-114 (1996).
67. Kidney Disease Outcomes Quality Initiative Clinical Practice Guidelines for Bone Metabolism and Disease in Chronic Kidney Disease [online], http://www.kidney.org/professionals/kdoqi/ guidelines-bone/Guide7.htm.
68. Yuan, W. et al. 1,25-dihydroxyvitamin D3 suppresses renin gene transcription by blocking the activity of the cyclic AMP response element in the renin gene promoter. J. Biol. Chem. 282, 29821-29830 (2007).
69. Tan, X., Li, Y. & Liu, Y. Paricalcitol attenuates renal interstitial fibrosis in obstructive nephropathy. J. Am. Soc. Nephrol. 17, 3382-3393 (2006).
70. Leheste, J. R. et al. Megalin knockout mice as an animal model of low molecular weight proteinuria. Am. J. Pathol. 155, 1361-1370 (1999).
71. Leheste, J. R. et al. Hypocalcemia and osteopathy in mice with kidney-specific megalin gene defect. FASEB J. 17, 247-249 (2003).
72. Matsui, I. et al. Active vitamin D and its analogue, 22-oxacalcitriol, ameliorate puromycin aminonucleoside-induced nephrosis in rats. Nephrol. Dial. Transplant. 24, 2354-2361 (2009).
73. Jacob, A. I., Sallman, A., Santiz, Z. & Hollis, B. W. Defective photoproduction of cholecalciferol in normal and uremic humans. J. Nutr. 114, 1313-1319 (1984).
74. Andress, D. L. Vitamin D in chronic kidney disease: a systemic role for selective vitamin D receptor activation. Kidney Int. 69, 33-43 (2006).
75. Li, Y., Spataro, B. C., Yang, J., Dai, C. & Liu, Y. 1,25-dihydroxyvitamin D inhibits renal interstitial myofibroblast activation by inducing hepatocyte growth factor expression. Kidney Int. 68, 1500-1510 (2005).
76. Schwarz, U. et al. effect of 1,25 (OH)2 vitamin D3 on glomerulosclerosis in subtotally nephrectomized rats. Kidney Int. 53, 1696-1705 (1998).
77. Xiao, H. et al. 1,25-Dihydroxyvitamin D(3) prevents puromycin aminonucleoside-induced apoptosis of glomerular podocytes by activating the phosphatidylinositol 3-kinase/Akt-signaling pathway. Am. J. Nephrol. 30, 34-43 (2009).
78. Okamura, M., Takano, Y., Saito, Y., Yao, J. & Kitamura, M. Induction of nephrin gene expression by selective cooperation of the retinoic acid receptor and the vitamin D receptor. Nephrol. Dial. Transplant. 24, 3006-3012 (2009).
79. Yamauchi, K. et al. Screening and identification of substances that regulate nephrin gene expression using engineered reporter podocytes. Kidney Int. 70, 892-900 (2006).
80. Wang, Y. et al. Altered vitamin D metabolism in type II diabetic mouse glomeruli may provide protection from diabetic nephropathy. Kidney Int. 70, 882-891 (2006).
81. Kuhlmann, A. et al. 1,25-Dihydroxyvitamin D3 decreases podocyte loss and podocyte hypertrophy in the subtotally nephrectomized rat. Am. J. Physiol. Renal Physiol. 286, F526-F533 (2004).
82. Li, Y. C. et al. 1,25-Dihydroxyvitamin D(3) is a negative endocrine regulator of the reninangiotensin system. J. Clin. Invest. 110, 229-238 (2002).
83. Pilz, S., Tomaschitz, A., Ritz, e. & Pieber, T. R. Vitamin D status and arterial hypertension: a systematic review. Nat. Rev. Cardiol. 6, 621-630 (2009).
84. Morris, K. L. & Zemel, M. B. 1,25-Dihydroxyvitamin D3 modulation of adipocyte glucocorticoid function. Obes. Res. 13, 670-677 (2005).
85. de Borst, M. H. et al. Specific MAP-kinase blockade protects against renal damage in homozygous TGR(mRen2)27 rats. Lab. Invest. 83, 1761-1770 (2003).
86. van Veldhuisen, D. J. et al. High- versus low-dose ACe inhibition in chronic heart failure: a doubleblind, placebo-controlled study of imidapril. J. Am. Coll. Cardiol. 32, 1811-1818 (1998).
87. Krikken, J. A., Laverman, G. D. & Navis, G. Benefits of dietary sodium restriction in the management of chronic kidney disease. Curr. Opin. Nephrol. Hypertens. doi:10.1097/ MNH.0b013e3283312fc8
88. Vogt, L., Waanders, F., Boomsma, F., de Zeeuw, D. & Navis, G. effects of dietary sodium and hydrochlorothiazide on the antiproteinuric efficacy of losartan. J. Am. Soc. Nephrol. 19, 999-1007 (2008).
89. Kramer, A. B., van der Meulen, e. F., van Goor, H. & Navis, G. effect of combining ACe inhibition with aldosterone blockade on proteinuria and renal damage in experimental nephrosis. Kidney Int. 71, 417-424 (2007).
90. Nguyen, G. et al. Pivotal role of the renin/ prorenin receptor in angiotensin II production and cellular responses to renin. J. Clin. Invest. 109, 1417-1427 (2002).
91. Hamming, I., Navis, G., Kocks, M. J. & van Goor, H. ACe inhibition has adverse renal effects during dietary sodium restriction in proteinuric and healthy rats. J. Pathol. 209, 129-139 (2006).
92. Mizobuchi, M. et al. Combination therapy with an angiotensin-converting enzyme inhibitor and a vitamin D analog suppresses the progression of renal insufficiency in uremic rats. J. Am. Soc. Nephrol. 18, 1796 - 1806 (2007).
93. van Paassen, P., de Zeeuw, D., Navis, G. & de Jong, P. e. Renal and systemic effects of continued treatment with renin inhibitor remikiren in hypertensive patients with normal and impaired renal function. Nephrol. Dial. Transplant. 15, 637-643 (2000).
94. Parving, H. H., Persson, F., Lewis, J. B., Lewis, e. J. & Hollenberg, N. K. Aliskiren combined with losartan in type 2 diabetes and nephropathy. N. Engl. J. Med. 358, 2433-2446 (2008).
95. Persson, F. et al. Renal effects of aliskiren compared to and in combination with irbesartan in patients with type 2 diabetes, hypertension and albuminuria. Diabetes Care 32, 1873-1879 (2009).
96. Yamamoto, e. et al. Aliskiren enhances the protective effects of valsartan against cardiovascular and renal injury in endothelial nitric oxide synthase-deficient mice. Hypertension 54, 633-638 (2009).
97. Batenburg, W. W. et al. Aliskiren-binding increases the half life of renin and prorenin in rat aortic vascular smooth muscle cells. Arterioscler. Thromb. Vasc. Biol. 28, 1151-1157 (2008).
98. Zhang, Z. et al. Combination therapy with AT1 blocker and vitamin D analog markedly ameliorates diabetic nephropathy: blockade of compensatory renin increase. Proc. Natl Acad. Sci. USA 105, 15896-15901 (2008).
99. Kramer, A. B., Laverman, G. D., van Goor, H. & Navis, G. Inter-individual differences in antiproteinuric response to ACei in established adriamycin nephrotic rats are predicted by pretreatment renal damage. J. Pathol. 201, 160-167 (2003).
100. Remuzzi, G. et al. Combining an antiproteinuric approach with mycophenolate mofetil fully suppresses progressive nephropathy of experimental animals. J. Am. Soc. Nephrol. 10, 1542-1549 (1999).
101. Panichi, V. et al. effects of 1,25(OH)2D3 in experimental mesangial proliferative nephritis in rats. Kidney Int. 60, 87-95 (2001).
102. Lemire, J. M., Adams, J. S., Sakai, R. & Jordan, S. C. 1 Alpha, 25-dihydroxyvitamin D3 suppresses proliferation and immunoglobulin production by normal human peripheral blood mononuclear cells. J. Clin. Invest. 74, 657-661 (1984).
103. Rigby, W. F., Stacy, T. & Fanger, M. W. Inhibition of T lymphocyte mitogenesis by 1,25-dihydroxyvitamin D3 (calcitriol). J. Clin. Invest. 74, 1451-1455 (1984).
104. Adams, J. S. & Hewison, M. Unexpected actions of vitamin D: new perspectives on the regulation of innate and adaptive immunity. Nat. Clin. Pract. Endocrinol. Metab. 4, 80-90 (2008).
105. Zehnder, D. et al. Reduction of the vitamin D hormonal system in kidney disease is associated with increased renal inflammation. Kidney Int. 74, 1343-1353 (2008).
106. Cohen-Lahav, M., Douvdevani, A., Chaimovitz, C. & Shany, S. The anti-inflammatory activity of 1,25-dihydroxyvitamin D3 in macrophages. J. Steroid Biochem. Mol. Biol. 103, 558-562 (2007).
107. Sigmundsdottir, H. et al. DCs metabolize sunlightinduced vitamin D3 to 'program' T cell attraction to the epidermal chemokine CCL27. Nat. Immunol. 8, 285-293 (2007).
108. Fritsche, J., Mondal, K., ehrnsperger, A., Andreesen, R. & Kreutz, M. Regulation of 25-hydroxyvitamin D3-1 alpha-hydroxylase and production of 1 alpha, 25-dihydroxyvitamin D3 by human dendritic cells. Blood 102, 3314-3316 (2003).
109. van etten, e. & Mathieu, C. Immunoregulation by 1,25-dihydroxyvitamin D3: basic concepts. J. Steroid Biochem. Mol. Biol. 97, 93-101 (2005).
110. Mora, J. R., Iwata, M. & von Andrian, U. H. Vitamin effects on the immune system: vitamins A and D take centre stage. Nat. Rev. Immunol. 8, 685-698 (2008).
111. Penna, G. & Adorini, L. 1 Alpha, 25-dihydroxyvitamin D3 inhibits differentiation, maturation, activation, and survival of dendritic cells leading to impaired alloreactive T cell activation. J. Immunol. 164, 2405-2411 (2000).
112. Adorini, L. & Penna, G. Dendritic cell tolerogenicity: a key mechanism in immunomodulation by vitamin D receptor agonists. Hum. Immunol. 70, 345-352 (2009).
113. Ghoreishi, M. et al. expansion of antigen-specific regulatory T cells with the topical vitamin D analog calcipotriol. J. Immunol. 182, 6071-6078 (2009).
114. Redaelli, C. A. et al. 1Alpha, 25-dihydroxyvitamin D3 shows strong and additive immunomodulatory effects with cyclosporine A in rat renal allotransplants. Kidney Int. 61, 288-296 (2002).
115. Courbebaisse, M. et al. effects of vitamin D supplementation on the calcium-phosphate balance in renal transplant patients. Kidney Int. 75, 646-651 (2009).
116. Heymann, F. et al. Kidney dendritic cell activation is required for progression of renal disease in a mouse model of glomerular injury. J. Clin. Invest. 119, 1286-1297 (2009).
117. Thiem, U. et al. VITA-D: cholecalciferol substitution in vitamin D deficient kidney transplant recipients: a randomized, placebocontrolled study to evaluate the post-transplant outcome. Trials 10, 36 (2009).